Cargando…

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2017
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490498/ https://www.ncbi.nlm.nih.gov/pubmed/28663202 http://dx.doi.org/10.1136/bmj.j3170

Ejemplares similares

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
por: Benn, Marianne, et al.
Publicado: (2017)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
por: Park, Sehoon, et al.
Publicado: (2023)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Correction: Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study
por: Linsel-Nitschke, Patrick, et al.
Publicado: (2008)

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries
por: Rosoff, Daniel B., et al.
Publicado: (2023)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
por: Alannan, Malak, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
por: Schmidt, Amand F, et al.
Publicado: (2017)

Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts
por: Cao, Lei, et al.
Publicado: (2016)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
por: Papotti, Bianca, et al.
Publicado: (2022)

A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease
por: Pierzchlińska, Anna, et al.
Publicado: (2021)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
por: Fang, Si, et al.
Publicado: (2023)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study
por: Linsel-Nitschke, Patrick, et al.
Publicado: (2008)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
por: Gadkar, K, et al.
Publicado: (2014)

Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9?
por: Soltanmohammadi, Elham, et al.
Publicado: (2016)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese
por: Chang, Xiao-Long, et al.
Publicado: (2016)

A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
por: Fowler, Alexandra, et al.
Publicado: (2023)

Investigating genetically mimicked effects of statins via HMGCR inhibition on immune-related diseases in men and women using Mendelian randomization
por: Yang, Guoyi, et al.
Publicado: (2021)

Electroacupuncture regulates hepatic cholesterol synthesis by HMGCR deubiquitination in rats
por: Jin, Shu-wen, et al.
Publicado: (2023)

Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk
por: Simmons, Christopher R, et al.
Publicado: (2011)

Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
por: Petersen-Uribe, Álvaro, et al.
Publicado: (2021)

Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study
por: Yan, Zhaoqi, et al.
Publicado: (2023)

Correction: Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease
por: Jones, Lesley, et al.
Publicado: (2011)

Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study
por: Ma, Li, et al.
Publicado: (2023)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9bugv82v20d1867i6cg899fhej